Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Endocrine 2CNS 2Breast 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Thyroid Neoplasms 8Carcinoma, Medullary 6Thyroid Cancer, Papillary 5Lung Neoplasms 4Breast Neoplasms 4Thyroid Diseases 3Sarcoma 3Neoplasms 3Colonic Neoplasms 3Central Nervous System Neoplasms 3Wilms Tumor 2Thoracic Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Diseases 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Ependymoma 2

Interventions

Carboplatin 15Pemetrexed 8Paclitaxel 6pembrolizumab 5osimertinib 4atezolizumab 4Gemcitabine 4Erlotinib Hydrochloride 4entinostat 3durvalumab 3Cisplatin 3selpercatinib 2pralsetinib 2camrelizumab 2apatinib 2Vinorelbine 2Radiosurgery 2Nivolumab 2Injections 2Gefitinib 2Bevacizumab 2130-nm albumin-bound paclitaxel 2toripalimab 1taletrectinib 1sotorasib 1sintilimab 1repotrectinib 1pegylated granulocyte colony-stimulating factor 1patritumab 1necitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thoracic Neoplasms × selpercatinib × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡